CEO Catherine Pickering describes a year of transformational progress paving the way for an exceptional 2026
As 2025 draws to a close, I am immensely proud of what we have achieved together at iOnctura. This year has been nothing short of transformative – a testament to the power of focus, agility, and unwavering commitment to patients.
Five phase II trials are now underway – three randomised against standard of care
We initiated five Phase II studies of our next-generation PI3Kδ inhibitor roginolisib this year – no mean feat for a small biotech. Notably, three are randomised against standard of care, in uveal melanoma, non small-cell lung cancer and chronic lymphocytic leukemia. This milestone underscores not only the scientific ambition behind our pipeline but also the operational excellence that defines iOnctura. Every trial is now recruiting well; with some ahead of schedule. This efficiency means patients can access potentially life-changing therapies faster – and that’s what drives us.
Advancing a global effort to deliver the next-generation of PI3Kδ therapy
iOnctura is unlocking the full potential of a target that others have tried and failed to drug safely and effectively. Our PI3Kδ inhibitor roginolisib continues to break new ground. In 2025, we expanded our clinical trial program into the United States, enabling us to serve patients better and collaborate with leading cancer centers such as Dana-Farber Cancer Institute. This global footprint strengthens our ability to generate robust evidence and accelerate access for patients who urgently need new options. We are proud to have treated over 180 people to date with roginolisib which will deliver a rich dataset across multiple indications over the coming year.
Cambritaxestat: Positive phase I results and a new horizon
Our second clinical asset, cambritaxestat, delivered encouraging results in its Phase I study presented at ESMO, meeting its primary endpoint of safety and tolerability in combination with standard chemotherapy in metastatic pancreatic cancer. These findings validate our scientific approach and pave the way for an expanded focus to include liver cancer, a critical area of unmet need.
Engaging with the patient community
Beyond the clinic, we actively supported and attended several patient advocacy conferences this year. These moments are deeply rewarding – they remind us why we do what we do. Meeting patients and advocates of patients with uveal melanoma and hearing their stories reinforces the urgency and importance of our mission.
Our aim is clear: to bring together six years of breakthrough science and exploration to create medicines that demonstrate measurable and definable benefit to patients-“prolonging life, whilst preserving its quality”.
Strengthening our leadership for the future
To prepare for the next chapter, we have expanded our executive leadership team and enhanced our Board with seasoned experts who bring deep experience in finance, operations, business development and oncology drug development. These appointments ensure we are well-positioned to deliver on our ambitious strategy and scale for success.
Looking ahead to 2026
As we step into 2026, our vision is clear: to deliver high precision small molecule therapies that promise to redefine treatment paradigms for cancers with high unmet need. With multiple trials progressing rapidly, we are poised for another year of bold innovation and meaningful impact.
To our dedicated team, partners, and investors – thank you for your trust and collaboration. Together, we are shaping a future where more patients can live longer, healthier lives.
